Logo

Xoma and Diversa Sign Antibody License and Development Agreement

Jan 06, 2004

NEW YORK, Jan. 6 (GenomeWeb News) - Xoma of Berkeley, Calif., and Diversa of San Diego have signed a licensing and development agreement, the companies said today.

 

Diversa will license Xoma's antibody expression technology as well as obtain an option for an antibody production license. In return, Xoma will receive a license fee and potential future milestone and royalty payments.

 

Xoma and Diversa also plan to co-develop antibodies for autoimmune-related diseases. Xoma will provide Diversa with research funding, and Diversa will be entitled to milestone and royalty payments on any drugs developed under the agreement.

 

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.